Literature DB >> 10477740

Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway.

Y Jing1, J Dai, R M Chalmers-Redman, W G Tatton, S Waxman.   

Abstract

Low concentrations of As(2)O(3) (</=1 micromol/L) induce long-lasting remission in patients with acute promyelocytic leukemia (APL) without significant myelosuppressive side effects. Several groups, including ours, have shown that 0.5 to 1 micromol/L As(2)O(3) induces apoptosis in APL-derived NB4 cells, whereas other leukemic cells are resistant to As(2)O(3) or undergo apoptosis only in response to greater than 2 micromol/L As(2)O(3). In this report, we show that the ability of As(2)O(3) to induce apoptosis in leukemic cells is dependent on the activity of the enzymes that regulate cellular H(2)O(2) content. Thus, NB4 cells have relatively low levels of glutathione peroxidase (GPx) and catalase and have a constitutively higher H(2)O(2) content than U937 monocytic leukemia cells. Glutathione-S-transferase pi (GSTpi), which is important for cellular efflux of As(2)O(3), is also low in NB4 cells. Moreover, As(2)O(3) further inhibits GPX activity and increases cellular H(2)O(2) content in NB4 but not in U937 cells. Selenite pretreatment of NB4 cells increases the activity of GPX, lowers cellular H(2)O(2) levels, and renders NB4 cells resistant to 1 micromol/L As(2)O(3). In contrast, concentrations of As(2)O(3) that alone are not capable of inducing apoptosis in NB4 cells induce apoptosis in the presence of the GPx inhibitor mercaptosuccinic acid. Similar effects are observed by modulating the activity of catalase with its inhibitor, aminotriazol. More important from a therapeutic point of view, U937 and HL-60 cells, which require high concentrations of As(2)O(3) to undergo apoptosis, become sensitive to low, clinically acceptable concentrations of As(2)O(3) when cotreated with these GPx and catalase inhibitors. The induction of apoptosis by As(2)O(3) involves an early decrease in cellular mitochondrial membrane potential and increase in H(2)O(2) content, followed by cytochrome c release, caspase 3 activation, DNA fragmentation, and the classic morphologic changes of apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477740

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  110 in total

Review 1.  Management of acute promyelocytic leukemia.

Authors:  Martin S Tallman; Chadi Nabhan
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

2.  Role of reactive oxygen species in arsenic-induced transformation of human lung bronchial epithelial (BEAS-2B) cells.

Authors:  Zhuo Zhang; Poyil Pratheeshkumar; Amit Budhraja; Young-Ok Son; Donghern Kim; Xianglin Shi
Journal:  Biochem Biophys Res Commun       Date:  2014-12-10       Impact factor: 3.575

3.  Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.

Authors:  J E Chang; P M Voorhees; J M Kolesar; H G Ahuja; F A Sanchez; G A Rodriguez; K Kim; J Werndli; H H Bailey; B S Kahl
Journal:  Hematol Oncol       Date:  2009-03       Impact factor: 5.271

4.  Arsenic trioxide induces apoptosis in human colorectal adenocarcinoma HT-29 cells through ROS.

Authors:  Young Cha; Dae-Weon Park; Chu Hee Lee; Suk-Hwan Baek; Seong-Yong Kim; Jae-Ryong Kim; Jung Hye Kim
Journal:  Cancer Res Treat       Date:  2006-02-28       Impact factor: 4.679

5.  Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

Authors:  Roberto R Rosato; Jorge A Almenara; Sonia C Maggio; Stefanie Coe; Peter Atadja; Paul Dent; Steven Grant
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

Review 6.  Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.

Authors:  Mary E Irwin; Nilsa Rivera-Del Valle; Joya Chandra
Journal:  Antioxid Redox Signal       Date:  2012-09-28       Impact factor: 8.401

7.  ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage.

Authors:  Xiaohua Peng; Varsha Gandhi
Journal:  Ther Deliv       Date:  2012-07

8.  Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.

Authors:  Elizabeth Fox; Bassem I Razzouk; Brigitte C Widemann; Shaun Xiao; Michelle O'Brien; Wendy Goodspeed; Gregory H Reaman; Susan M Blaney; Anthony J Murgo; Frank M Balis; Peter C Adamson
Journal:  Blood       Date:  2007-10-24       Impact factor: 22.113

9.  Variability in sensitivity to arsenite does not correlate with arsenic accumulation rate in normal human lymphoblasts.

Authors:  Ping Li; Ahmed N Uddin; Zijuan Liu; Rita Mukhopadhyay; Elena V Komissarova; Barry P Rosen; Toby G Rossman
Journal:  Mol Cell Biochem       Date:  2004-01       Impact factor: 3.396

10.  Transcriptional activation of metalloid tolerance genes in Saccharomyces cerevisiae requires the AP-1-like proteins Yap1p and Yap8p.

Authors:  Robert Wysocki; Pierre-Karl Fortier; Ewa Maciaszczyk; Michael Thorsen; Anick Leduc; Asa Odhagen; Grzegorz Owsianik; Stanislaw Ulaszewski; Dindial Ramotar; Markus J Tamás
Journal:  Mol Biol Cell       Date:  2004-02-20       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.